Basics Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. IPO Date: May 11, 2017 Sector: Healthcare Industry: Biotech Market Cap: $1.5B Activated in VL: True Average Daily Range Avg Daily Range: $1.22 | 2.61% Avg Daily Range (30 D): $0.44 | 3.15% Avg Daily Range (90 D): $0.68 | 3.68% Institutional Daily Volume Avg Daily Volume: .75M Avg Daily Volume (30 D): 1.7M Avg Daily Volume (90 D): 1.82M Trade Size Avg Trade Size (Sh.): 79 Avg Trade Size (Sh.) (30 D): 84 Avg Trade Size (Sh.) (90 D): 82 Institutional Trades Total Inst.Trades: 5,262 Avg Inst. Trade: $3.09M Avg Inst. Trade (30 D): $2.06M Avg Inst. Trade (90 D): $2.16M Avg Inst. Trade Volume: .06M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $4.96M Avg Closing Trade (30 D): $3.05M Avg Closing Trade (90 D): $3.49M Avg Closing Volume: 106.01K     News Aug 2, 2025 @ 7:02 PM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages B... Source: Rosen Law Firm Aug 2, 2025 @ 3:49 PM Bragar Eagel & Squire, P.C. Urges Investors in XPL... Source: Bragar Eagel & Squire, P.C. Aug 1, 2025 @ 2:45 PM SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investi... Source: James (Josh) Wilson Jul 31, 2025 @ 4:00 PM Deadline Alert: Biohaven Ltd. (BHVN) Investors Who... Source: Glancy Prongay & Murray Llp Jul 30, 2025 @ 4:00 PM DEADLINE ALERT for HIMS, IRBT, CNC, BHVN: Law Offi... Source: Law Offices Of Howard G. Smith Financials   TTM Q1 2025 Q3 2024 Basic EPS $-2.17 $-1.7 Diluted EPS $-2.17 $-1.7 Revenue $ $ M $ M Gross Profit $ $ $ Net Income / Loss $ $ -221.68M $ -160.3M Operating Income / Loss $ $ -221.56M $ -178.17M Cost of Revenue $ $ $ Net Cash Flow $ $ .15M $ -154.3M PE Ratio